1 year return (CAGR)
-
Liminatus Pharma, Inc. Class A Common Stock Exchange (NASDAQ, USD)
LIMN
4.07
+0.43 (+11.81%)
HealthcareBiotechnology
Loading...
3 year return (CAGR)
-
5 year return (CAGR)
-
10 year return (CAGR)
-
Objective Corporation Stock Analysis – State Within State
Read MoreMarketcap
5.47M
Price/Sales
-
Ent value
5.55M
Price/Book
18.19
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
0.00%
Trailing P/E
-
PEG
-
Forward P/E
-
EPS growth
-
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 3.71 |
| Daily high | 4.26 |
| Daily low | 3.64 |
| Daily Volume | 88K |
| All-time high | 5.16 |
| 1y analyst estimate | - |
| Beta | 0.74 |
| EPS (TTM) | -26.36 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| LIMN | S&P500 | |
| Current price drop from All-time high | -21.12% | -0.58% |
| Highest price drop | -95.17% | -56.47% |
| Date of highest drop | 6 Aug 2026 | 9 Mar 2009 |
| Avg drop from high | -67.14% | -10.68% |
| Avg time to new high | 25 days | 12 days |
| Max time to new high | 136 days | 1805 days |
News
